EP. 1: Dr Kami J. Maddocks Highlights Progress of Last 5 Years in DLBCL
May 2nd 2022Kami J. Maddocks, MD, professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, spoke with The American Journal of Managed Care® (AJMC®) about treatment approaches for diffuse large B-cell lymphoma (DLBCL).
Read More
EP. 2: Moffitt’s Dr Julio Chavez Discusses New Treatment, Sequencing Options in DLBCL
May 22nd 2022Julio Chavez, MD, MS, of Moffitt Cancer Center, spoke with The American Journal of Managed Care® (AJMC®) about how new approvals will alter decision making in the treatment of diffuse large B-cell lymphoma (DLBCL).
Read More
EP. 3: Zelenetz Discusses How to Evaluate Responses to Therapy in DLBCL
June 22nd 2022Andrew Zelenetz, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, is the current chair of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network (NCCN).
Read More
EP. 6: Fakhri Reviews Considerations for Second-Line Therapy in DLBCL
August 16th 2022Nearly 5 years after approval of the first CAR T-cell therapy, treatment is moving into second line, and patients have more options than ever for diffuse large B-cell lymphoma. How do physicians choose? Bita Fakhri, MD, MPH, hematologist-oncologist at the University of California San Francisco, discusses the process.
Read More